Amicus Therapeutics Inc., of Cranbury, N.J., reported that following a successful presubmission meeting with the EMA to discuss the registration of its oral small-molecule chaperone migalastat monotherapy for the treatment of Fabry disease, it has begun preparing a marketing authorization application that it plans to submit to the agency in the middle of 2015 under the centralized procedure.